<?php
/**
 * Forum topic creation script for DA-1726
 * Generated: 2026-11-09 (automated daily discovery pipeline)
 *
 * This script cannot be run via SSH from the remote agent.
 * To create the forum topic, either:
 *   1. SCP this file to the blog server and run: php /path/to/20261109_da-1726.php
 *   2. Use the WordPress REST API once blog.minmaxmuscle.com is on the network allowlist
 *   3. Create the topic manually in the Asgaros Forum admin panel
 *
 * Forum: blog.minmaxmuscle.com (Asgaros Forum plugin)
 * Target board: Peptide Research (or Metabolic & Weight Loss sub-board)
 */

// WordPress bootstrap - adjust path to your WP installation
// define('ABSPATH', '/path/to/wordpress/');
// require_once ABSPATH . 'wp-load.php';

$topic_title   = 'New Research Thread: DA-1726 (Oxyntomodulin Analog) — Phase 1 Liver Fat & Weight Data';
$topic_content = <<<EOT
<strong>Compound:</strong> DA-1726
<strong>Developer:</strong> MetaVia Inc.
<strong>Mechanism:</strong> Dual GLP-1R/glucagon receptor agonist (oxyntomodulin analog)
<strong>Stage:</strong> Phase 1 (Part 3B interim data, Q4 2026 topline pending)
<strong>Administration:</strong> Once-weekly subcutaneous injection

<strong>7-Day Trigger (November 6, 2026):</strong> Interim Phase 1 Part 3B results presented at the Precision Liver Symposium 2026 in Denver:
- Placebo-adjusted body weight reduction: <strong>13.5%</strong>
- Placebo-adjusted liver fat reduction (MRI-PDFF): <strong>68%</strong>
- n=19 (15 drug, 4 placebo); doses 48 mg and 64 mg weekly

<strong>Upcoming:</strong> ObesityWeek 2026 poster November 14, 2026: "DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide"

<strong>Mechanism vs. other drugs:</strong>
- vs. semaglutide: adds glucagon receptor (thermogenesis + liver fat oxidation)
- vs. tirzepatide: targets glucagon receptor instead of GIP receptor — more hepatic-specific
- vs. retatrutide: dual (GLP-1R + GCGR) vs. triple agonist (GLP-1R + GIPR + GCGR)

<strong>Indications:</strong> Obesity, MASLD, MASH, MetALD, ALD

<strong>Dossier:</strong> https://minmaxmuscle.com/peptides/da-1726
<strong>Blog post:</strong> https://blog.minmaxmuscle.com/da-1726-oxyntomodulin-glp1-glucagon-masld-obesity-phase1-research-dossier/

<em>Research compounds discussed for educational purposes. Not FDA-approved for human use. Consult a healthcare provider before use.</em>
EOT;

/*
 * Example using Asgaros Forum REST endpoint (if available):
 *
 * curl -X POST https://blog.minmaxmuscle.com/wp-json/asgaros-forum/v1/topics \
 *   -H "Authorization: Basic $(echo -n "${WP_USER}:${WP_APP_PASSWORD}" | base64)" \
 *   -H 'Content-Type: application/json' \
 *   -d '{"title": "...", "content": "...", "board_id": BOARD_ID}'
 *
 * Or via WP post type (fallback):
 * curl -X POST https://blog.minmaxmuscle.com/wp-json/wp/v2/posts \
 *   -H "Authorization: Basic $(echo -n "${WP_USER}:${WP_APP_PASSWORD}" | base64)" \
 *   -H 'Content-Type: application/json' \
 *   -d '{"title":"New Research Thread: DA-1726","content":"...","status":"publish"}'
 */

echo "Forum topic for DA-1726 ready to post.\n";
echo "Title: " . $topic_title . "\n";
echo "To apply: SCP to server and run, or post manually via WP admin > Asgaros Forum\n";
